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Abstract
Introduction: Increased animal fat consumption is associated with increased premenopausal breast cancer risk in
normal weight, but not overweight, women. This agrees with our previous findings in obesity-resistant BALB/c
mice, in which exposure to a high saturated animal fat diet (HFD) from peripuberty through adulthood promoted
mammary tumorigenesis. Epidemiologic and animal studies support the importance of puberty as a life stage when
diet and environmental exposures affect adult breast cancer risk. In this study, we identified the effects of
peripubertal exposure to HFD and investigated its mechanism of enhancing tumorigenesis.
Methods: Three-week-old BALB/c mice fed a low-fat diet (LFD) or HFD were subjected to 7,12-
dimethylbenz[a]anthracene (DMBA)-induced carcinogenesis. At 9 weeks of age, half the mice on LFD were
switched to HFD (LFD-HFD group) and half the mice on HFD were switched to LFD (HFD-LFD group). Tumor gene
expression was evaluated in association with diet and tumor latency.
Results: The peripubertal HFD reduced the latency of DMBA-induced mammary tumors and was associated with
tumor characteristics similar to those in mice fed a continuous HFD. Notably, short-latency tumors in both groups
shared gene expression characteristics and were more likely to have adenosquamous histology. Both HFD-LFD and
continuous HFD tumors showed similar gene expression patterns and early latency. Adult switch from HFD to LFD
did not reverse peripubertal HFD tumor promotion. Increased proliferation, hyperplasia, and macrophages were
present in mammary glands before tumor development, implicating these as possible effectors of tumor
promotion. Despite a significant interaction between pubertal diet and carcinogens in tumor promotion,
peripubertal HFD by itself produced persistent macrophage recruitment to mammary glands.
Conclusions: In obesity-resistant mice, peripubertal HFD is sufficient to irreversibly promote carcinogen-induced
tumorigenesis. Increased macrophage recruitment is likely a contributing factor. These results underscore the
importance of early life exposures to increased adult cancer risk and are consistent with findings that an HFD in
normal weight premenopausal women leads to increased breast cancer risk. Notably, short-latency tumors
occurring after peripubertal HFD had characteristics similar to human basal-like breast cancers that predominantly
develop in younger women.
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Introduction
Diets high in saturated fat (e.g., a Western diet), as well
as high body mass index (BMI) and obesity, have been
implicated as risk factors for breast cancer. However,
clear delineation of the roles of dietary fat vs. obesity in
relation to risk and to breast cancer subtypes is complex
(reviewed in [1, 2]). There is increasing consideration of
the importance of the time during the life course when
diet and/or obesity affect risk. High BMI is associated
with decreased risk of estrogen receptor– and progester-
one receptor–positive (ER + PR+) premenopausal breast
cancers, but it is also associated with increased risk of
premenopausal triple-negative breast cancer in African
American women [3]. Regardless of race, both luminal
ER + PR+ and triple-negative breast cancers are associ-
ated with obesity during the postmenopausal period [3].
Emerging evidence indicates that high total fat intake
tends to increase breast cancer risk [4]. Notably, in-
creased consumption of animal fat in red meat is associ-
ated with increased premenopausal breast cancer risk;
importantly, animal fat consumption increased breast
cancer in normal weight women but not in overweight
and obese women [5]. This report of Farvid et al. [5] is
in accord with our previous studies [6], in which we
found that a diet high in saturated animal fat (HFD)
promoted mammary tumor development in obesity-
resistant BALB/c mice. Additional epidemiologic evi-
dence and animal studies support the importance of the
pubertal period, a time of rapid breast development, as a
time in the life course when diet and environmental ex-
posures can affect breast cancer risk in adulthood. This
has important relevance for early-life prevention strat-
egies to reduce breast cancer.
We have investigated the effects of HFD initiated in
peripuberty and continued throughout adulthood on the
development of carcinogen-induced breast cancers in
obesity-resistant BALB/c mice [6]. Using this experimental
design, we found that HFD caused significant changes in
mammary glands before the development of tumors, such
as increased numbers of mammary epithelial hyperplastic
lesions, enhanced mammary cell proliferation, increased
growth and inflammatory factor gene expression, in-
creased mammary gland chemokine and cytokine gene ex-
pression associated with immunosuppressive regulatory T
cells, increased vascularization, and elevated numbers of
M2 macrophages. Furthermore, HFD dramatically re-
duced tumor latency, and the early developing tumors
exhibited gene expression patterns similar to human
basal-like breast cancers. Also noteworthy was the finding
that HFD did not cause significant weight gain or obesity
or significant changes in blood levels of insulin, glucose,
estrogen, or progesterone. Importantly, these findings in-
dicate a potential risk from HFD for a broader segment of
the population than only those who become obese, an
observation that is consistent with recent epidemiological
studies [5].
The present study was undertaken to identify the spe-
cific effects of exposure to HFD in peripuberty vs. adult-
hood, as well as to further investigate the mechanistic
basis of dietary animal fat effects that contribute to en-
hanced tumor development. Using the same animal
model, we found that a relatively short exposure to HFD
limited to the peripubertal period was sufficient to in-
crease mammary cell proliferation, mammary hyperpla-
sia development, and macrophage recruitment. Further,
these effects were sustained and not reversed after chan-
ging to a low-fat diet (LFD). Decreased tumor latency
was also observed when exposure to HFD was limited to
peripuberty. Notably, the early developing tumors exhib-
ited similar gene expression and histopathological charac-
teristics as those observed after continuous HFD exposure.
There was also increased occurrence of an ER − PR−
phenotype among early developing tumors, regardless of
their histopathology. Interestingly, only HFD exposure re-
stricted to adulthood resulted in body weight gain, but this
did not have a promotional effect on tumor development
compared with continuous exposure to either LFD or
HFD. These findings further implicate peripubertal HFD in
itself as a potential mammary cancer risk factor.
Methods
Animals
Three-week-old female BALB/c mice were purchased
from Charles River Laboratories (Portage, MI, USA).
Mothers of these mice were maintained on a LabDiet
5L79 diet (LabDiet, St. Louis, MO, USA) before and dur-
ing pregnancy and while nursing. Upon arrival, mice
were randomly distributed into two nonisocaloric diet
groups: LFD or HFD. Animals were housed in polysul-
fone cages and received food and water ad libitum. Food
consumption was monitored over a 24-h period weekly,
and the weight of food consumed in each diet was simi-
lar. Housing facilities were maintained on a 12:12-h
light-dark cycle at 20–24 °C with 40–50 % relative hu-
midity. All animal experimentation was conducted in ac-
cordance with accepted standards of humane animal
care and approved by the All University Committee on
Animal Use and Care at Michigan State University.
Diets were initiated at 3 weeks of age. At 9 weeks of age,
half the mice on LFD were switched to HFD (LFD-HFD
mice, n = 45) and half the mice on HFD were switched to
LFD (HFD-LFD mice, n = 42). The remaining mice on
HFD (n = 101) or LFD (n = 90) were kept on the same diets
for the duration of the experiments. Among the animals in
the analyses presented here were mice subjected to 7,12-
dimethylbenz[a]anthracene (DMBA)-induced tumorigen-
esis in our initial study comparing continuous HFD with
LFD [6]. For all groups, the experimental period ended at
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45 weeks of age. The detailed composition of the diets is
described in Additional file 1: Table S1.
Tumorigenesis
Mice were treated with DMBA (Sigma-Aldrich, St.
Louis, MO, USA) prepared in vegetable oil and adminis-
tered by oral gavage (50 mg/kg body weight/mouse)
once per week for 4 weeks starting at 5 weeks of age.
Additional control mice were kept on the same diet pro-
tocols but were not treated with DMBA. Body weights
were monitored weekly, and animals were palpated for
tumors once per week starting at 8 weeks after the first
DMBA dose. Tumor volume was measured twice per
week and harvested at 1-cm size. Two hours before be-
ing killed, mice were injected with 5-bromo-2′-deoxyuri-
dine (BrdU) (70 μg/g body weight; Sigma-Aldrich) for
analysis of cellular proliferation. At termination of all
feeding studies, portions of tumors and mammary tis-
sues were either snap-frozen for protein and RNA isola-
tion or formalin-fixed and either processed as whole
mounts [7] or paraffin-embedded for hematoxylin and
eosin (H&E) staining and immunohistochemistry [8].
Whole-mount preparations of glands and H&E sections
were scored for overall morphology and the presence of
hyperplasia and neoplasia [9]. All lesions and tumors were
reviewed and classified as previously described [10].
Metabolic parameters
Plasma glucose and insulin levels were metabolic param-
eters measured as previously described [6]. Nonfasting,
randomly sampled glucose and insulin levels were ob-
tained from mice fed ad libitum as an appropriate and
acceptable method based on mouse feeding habits and
the stress caused by fasting [11]. Plasma levels of glucose
were determined by ACCU-CHEK Compact glucometer
(Roche Diagnostics, Indianapolis, IN, USA), and insulin
levels were determined with an insulin enzyme-linked
immunosorbent assay kit from EMD Millipore (catalog
number EZRMI-13K; Billerica, MA, USA), following the
manufacturer’s instructions.
Immunofluorescence and immunohistochemical analyses
Detection of ERα, PR, and HER2/Neu was performed as
previously described [6]. ERα was detected with mouse
anti-ERα [1:10 in phosphate-buffered saline (PBS)–0.5 %
Triton X-100, catalog number NCL-ER-6F11; Leica Bio-
systems, Newcastle upon Tyne, UK) followed by Alexa
Fluor 488–labeled goat anti-mouse secondary antibody
(Ab) (1:200 in PBS; Life Technologies, Grand Island, NY,
USA). PR was detected with rabbit anti-PR (1:200 in 2 %
bovine serum albumin in phosphate-buffered saline
(PBSA), catalog number A0092; DAKO, Carpinteria,
CA, USA) followed by Alexa 488–labeled goat anti-
rabbit secondary Ab (1:200 in PBS; Life Technologies).
For HER2/Neu, sections were not blocked but immedi-
ately incubated with goat anti-Neu (1:50 in PBS, catalog
number sc-284-G; Santa Cruz Biotechnology, Santa
Cruz, CA, USA) followed by incubation with an Alexa
Fluor 488–labeled donkey anti-goat secondary Ab (1:400
in PBS; Life Technologies). For ERα and HER2/Neu as-
sessment, a minimum of 1000 cells were counted for
each tumor. Tumors were considered to be ERα-positive
(ER+) if 10 % or more of the total cells counted were ER+
[12]. A minimum of 500 cells per section for each tumor
were counted.
β-catenin was detected with rabbit polyclonal anti-β-
catenin (1:200 in 1 % PBSA, catalog number C2206-
1 ml; Sigma-Aldrich) at 4 °C overnight, followed by
Alexa Fluor 488–labeled goat anti-rabbit secondary Ab
(1:400 in PBS; Life Technologies). To analyze overall β-
catenin fluorescence intensity, the average pixel intensity
of all positively stained cells within the ductal epithelium
was determined. A threshold was set to exclude back-
ground fluorescence, and images were gated to include
intensity measurements only from positively staining
epithelial cells. To assess nuclear localization of β-
catenin, a nuclear β-catenin score between 1 and 5 was
assigned to each tumor by two independent evaluators,
where 1 was the absence of nuclear β-catenin and 5 was
more than 50 % of cells expressing nuclear β-catenin.
Analysis of macrophages in mammary gland or tumor
sections was performed as previously described [6].
Macrophages were detected with rat monoclonal anti-
F4/80 (1:75 in PBS–0.5 % Triton X-100, catalog number
MCA497R; AbD Serotec, Raleigh, NC, USA), followed
by incubation with Alexa 488–labeled goat anti-rat sec-
ondary Ab (1:100 in PBS; Life Technologies). M2-
activated macrophages were detected by double-labeling
with rat monoclonal anti-F4/80 and goat anti-arginase 1
(anti-Arg1) (1:200 in PBS–0.5 % Triton X-100, catalog
number sc-18354; Santa Cruz Biotechnology), followed
by appropriate secondary antibodies conjugated with
fluorescent labels. The number of F4/80 and/or Arg1-
positive cells was expressed as cells per structure in the
mammary gland periepithelial area and cells per image
in tumor samples.
Detection of BrdU incorporation was used as a meas-
ure of proliferation as previously described [6]. BrdU in-
corporation was detected with mouse anti-BrdU (1:100
in PBS–0.5 % Triton X-100, catalog number ab27958;
Abcam, Cambridge, MA, USA), followed by Alexa Fluor
488–labeled goat anti-mouse secondary Ab (1:200 in
PBS; Life Technologies). A minimum of 1000 cells were
counted for each section, and a minimum of 2–3 tissue
sections per animal were analyzed.
All immunofluorescence sections were counterstained
with 4′,6-diamidino-2-phenylindole. The stained sections
were visualized with a Nikon Eclipse TE2000-U
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fluorescence microscope (Nikon, Melville, NY, USA) using
a 40× lens objective, and the captured fluorescence
images were analyzed using MetaMorph software
(Molecular Devices, Sunnyvale, CA, USA). Histo-
logical sections of mammary glands stained for mac-
rophages and cellular proliferation were analyzed by
mammary gland epithelial structure: ducts or hyper-
plastic foci. Hyperplastic structures had multiple cell
layers of noticeably distorted epithelium compared
with normal epithelial structures.
CD31 staining was used to detect blood vessels as
previously described [6]. CD31 was detected with
rabbit anti-CD31 (1:50 in PBS–0.5 % Triton X-100,
catalog number AP15436PU-N; Acris Antibodies, San
Diego, CA, USA), followed by secondary swine anti-
rabbit Ab (DAKO) and VECTASTAIN ABC reagent
(PK-7100; Vector Laboratories, Burlingame, CA,
USA). The sections were then incubated with metal-
enhanced 3,3′-diaminobenzidine substrate solution
(1:10 dilution with Pierce stable peroxide substrate buf-
fer; Thermo Scientific, Rockford, IL, USA) and counter-
stained with hematoxylin. The stained sections were
visualized with a Nikon Eclipse E400 light microscope
(Nikon) using a 40× lens objective. A minimum of 1000
cells were counted for each section, and a minimum of
2–3 tissue sections per animal were analyzed. Digital mi-
crographs were captured and quantified as previously
described [6]. Blood vessel density was expressed as the
percentage of CD31-positive squares.
Quantitative reverse transcription polymerase chain
reaction analysis
Total RNA was isolated from mouse inguinal mammary
glands or tumors, cDNAs were prepared, and quantitative
reverse transcription polymerase chain reaction (qRT-
PCR) was performed as previously described [6]. Primers
for the following selected RNAs were purchased from
SABiosciences (Frederick, MD, USA): transforming
growth factor α (Tgfa) (PPM03051G), chemokine (C-C
motif) ligand 1 (Ccl1) (PPM03138C), Ccl17 (PPM02963B),
Ccl20 (PPM03142B), Ccl22 (PPM02950B), transforming
growth factor β1 (Tgfb1) (PPM02991B), neurotrophin 3
(Ntf3) (PPM04325A), transformation-related protein 53
(Trp53) (PPM02931C), cyclin D2 (Ccnd2) (PPM02900F),
catenin (cadherin associated protein), beta 1 (Ctnnb1)
(PPM03384A), breast cancer 1, early onset (Brca1)
(PPM03442A), apoptotic peptidase activating factor 1
(Apaf1) (PPM03407F), bone morphogenetic protein 7
(Bmp7) (PPM03001C), Bmp10 (PPM04457A), hypoxan-
thine-guanine phosphoribosyltransferase (PPM03559F),
and heat shock protein 90 alpha (cytosolic), class B mem-
ber 1 (PPM04803F). The RNAs analyzed for each treat-
ment group are presented in Additional file 2: Table S2.
Microarray analysis
Agilent Technologies (Santa Clara, CA, USA) 4 × 44K
whole mouse genome microarrays were performed ac-
cording to the manufacturer’s protocol with linear amp-
lification and two-color hybridization using total RNA
isolated from mouse mammary tumors (Additional file
2: Table S2). The reference channel was universal mouse
reference (as described in [13]) and was labeled with cy-
anine 5. Spots that had intensity greater than 10 dpi in
at least 80 % of samples were selected for subsequent
analysis. Data were Lowess-normalized, and missing data
were imputed using k-nearest neighbors with k = 10. A
total of 25 microarrays were analyzed. Two-class signifi-
cance analysis of microarrays was performed to identify
differentially expressed genes between early vs. late
tumor onset and HFD vs. LFD. All statistical analyses
were conducted in R using the limma package in Bio-
conductor. For genes significantly associated (p < 0.05)
with early vs. late tumor onset, gene ontology analyses
were conducted using Ingenuity Pathway Analysis (QIA-
GEN, Redwood City, CA, USA). The data discussed in
this publication have been deposited in the National
Center for Biotechnology Information Gene Expression
Omnibus (GEO) [14] database and are accessible at ac-
cession number [GEO:GSE73983] [15].
Statistical analyses
qRT-PCR assays were statistically analyzed using propri-
etary software from SABiosciences. Otherwise, the re-
sults were expressed as mean ± standard error of the
mean. Differences were considered significant at p < 0.05
using Student’s t test or analysis of variance followed by
a Tukey’s multiple-comparisons test, as appropriate.
Tumor incidence was analyzed by the χ2 test. Tumor la-
tencies were determined from Kaplan-Meier plots.
Results
Peripubertal exposure to high-fat diet promotes
tumorigenesis
Mice were fed HFD or LFD during peripuberty, from 3
to 9 weeks of age, and then switched to LFD (HFD-LFD)
or HFD (LFD-HFD), respectively, for the remainder of
the experimental period up to 45 weeks of age. Two
additional groups of mice were fed HFD or LFD starting
at 3 weeks of age and continuing to 45 weeks of age
(Fig. 1a). Kaplan-Meier plots show similar tumor inci-
dence and latency patterns for the HFD-LFD and con-
tinuous HFD (HFD) groups (Fig. 1b), as well as for the
continuous LFD (LFD) and LFD-HFD groups (Fig. 1c).
Although the trends of increased incidence and de-
creased latency of the HFD-LFD group did not reach
statistical significance compared with the LFD-HFD
group (Fig. 1d), the overall pattern was similar to
continuous HFD vs. continuous LFD (Fig. 1e). The
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Kaplan-Meier plots for LFD vs. LFD-HFD and HFD vs.
HFD-LFD were almost identical and not statistically dif-
ferent (Fig. 1b, c). These results indicate that the short
period of 6 weeks on HFD during the peripubertal
period (HFD-LFD group) had effects on tumor incidence
and latency similar to those of mice fed continuously on
HFD from puberty through adulthood up to 45 weeks of
age. Furthermore, the switch from HFD to LFD in adult-
hood did not reverse the effects of peripubertal HFD on
tumor promotion.
Tumor characteristics
Analysis of the tumor characteristics of histopathology,
time to tumor development, and receptor status (Table 1)
showed that 6 mice in the HFD-LFD group (n = 11) de-
veloped tumors less than 23 weeks after DMBA expos-
ure, before any tumor incidence in the LFD-HFD group.
These tumors were almost exclusively adenosquamous
carcinomas and ER−, PR−, and Her2−. This is in con-
trast to the majority of tumors that developed later
(≥23 weeks after DMBA exposure) in the LFD-HFD and
Fig. 1 Experimental design and Kaplan-Meier plot of 7,12-dimethylbenz[a]anthracene (DMBA)-induced mammary tumors. a BALB/c mice were
started on a high saturated animal fat diet (HFD) or a low-fat diet (LFD) at 3 weeks old. Mice were switched from HFD to LFD and from LFD to
HFD at 9 weeks old. DMBA was administered weekly from ages 5 to 8 weeks. Tumor incidence was observed. b–e Kaplan-Meier plots of tumor
incidence. Time = number of days after last DMBA treatment (HFD mice, n = 101; LFD mice, n = 90; HFD-LFD mice, n = 42; LFD-HFD mice, n = 45).
b HFD-LFD vs. HFD. c LFD-HFD vs. LFD. d LFD-HFD vs. HFD-LFD. e LFD vs. HFD
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HFD-LFD groups. There was no significant difference in
the incidence proportion of ER+ and ER− glandular,
cribriform, or papillary carcinomas between the later-
developing tumors in the HFD-LFD and LFD-HFD
groups (i.e., HFD-LFD late tumors, 3 of 5 ER+; LFD-HFD
tumors, 4 of 6 ER+). The overall proportion of adenosqua-
mous tumors in the HFD-LFD group was significantly
higher than in the LFD-HFD group (p < 0.05) (Fig. 2a).
The tumor latency of adenosquamous tumors was signifi-
cantly shorter than that for all other tumor types in the
HFD-LFD and LFD-HFD groups (p < 0.05) (Fig. 2b). The
latency of nonadenosquamous tumors did not differ sig-
nificantly between the HFD-LFD and LFD-HFD groups.
Analysis of tumor cell proliferation showed that tu-
mors in the HFD-LFD group collectively, as well as
adenosquamous tumors specifically, exhibited signifi-
cantly higher proliferation than tumors in the LFD-
HFD group (p < 0.05) (Fig. 2c). A similar analysis was
carried out among continuous HFD and LFD groups.
There were no significant differences in the percent-
age of adenosquamous or other tumor types between
the two diets (Fig. 2d). However, the HFD adenosqua-
mous tumors had a significantly shorter latency
(Fig. 2e) and significantly higher cell proliferation (Fig. 2f)
than adenosquamous tumors that arose in mice on LFD
(p < 0.05). There was equal representation of high-grade
epithelial tumors across all diet treatments and early vs.
late tumors (data not shown).
There were notable similarities between tumors devel-
oping on continuous HFD and on HFD restricted to
peripuberty. Namely, both groups had early-onset ade-
nosquamous tumors (reduced latency <23 weeks follow-
ing exposure) and increased cell proliferation. Tumors
with other histopathologies (i.e., glandular, cribriform,
and papillary carcinomas) also showed significantly re-
duced latency in mice on continuous HFD compared
with those on LFD (p < 0.05) (Fig. 2e), indicating that
HFD also affects onset of these tumor types. These
effects on continuous HFD-fed animals suggest that,
although the peripubertal window may be especially
sensitive, the effects of HFD persist in later adult-
hood. Furthermore, short-latency tumors occurring in
both HFD and HFD-LFD mice showed a higher inci-
dence of an ER−PR− phenotype than tumors in all
other treatment groups (Fig. 2g). All ER−PR− tumors
(Table 1) tested for Her2 were negative for that
marker (data not shown).
We previously determined that continuous HFD treat-
ment resulted in short-latency tumors that also had sig-
nificant changes in angiogenesis and macrophage
recruitment [6]. Thus, we analyzed these same proper-
ties in all tumors that developed in the HFD-LFD and
LFD-HFD groups, and we compared the results to all tu-
mors obtained with continuous diet treatments. Tumors
from HFD-LFD mice had significantly increased angio-
genesis compared with LFD tumors, similar to that
Table 1 Tumor characteristics
Diet Weeks after first DMBA treatment Histopathology Hormone receptor statusa
LFD-HFD 23 Glandular/spindle cell carcinoma ER−PR−
28 Papillary carcinoma ER−PR−
31 Glandular carcinoma ER+PR+
37 Glandular carcinoma ER+PR+
38 Papillary carcinoma ER+PR+
42 Glandular carcinoma ER+PR+
HFD-LFD-early 10 Adenosquamous carcinoma ER−PR−
10 Adenosquamous carcinoma ER−PR−
16 Adenosquamous carcinoma ER−PR−
14 Adenosquamous carcinoma ER−PR−
17 Adenosquamous carcinoma ER−PR−
19 Cribriform carcinoma ER−PR−
HFD-LFD-late 26 Papillary carcinoma ER−PR−
28 Papillary carcinoma ER+PR+
33 Glandular carcinoma ER+PR+
35 Glandular carcinoma ER+PR+
38 Adenosquamous carcinoma ER−PR−
DMBA 7,12-dimethylbenz[a]anthracene, ER estrogen receptor, HFD high saturated animal fat diet, LFD low-fat diet, PR progesterone receptor
aER status was based on >10 % receptor-positive cell. All ER−PR− tumors that were tested were also Her2−
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Fig. 2 (See legend on next page.)
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observed in continuous HFD tumors (Fig. 3a). There
was also a trend toward increased angiogenesis in LFD-
HFD tumors (p = 0.07). Analysis of macrophage
localization in tumors showed that, compared with LFD-
HFD tumors, there were significantly increased numbers
of macrophages within the stroma of HFD-LFD tumors
(Fig. 3b). There was no difference in the level of Arg1-
positive, alternatively activated macrophages between
HFD-LFD and LFD-HFD tumors (Fig. 3b). Taken to-
gether, these results indicate that increased angiogenesis
and macrophage recruitment were likely contributors to
tumor promotion in HFD-LFD mice. Interestingly, be-
cause LFD-HFD tumors showed trends toward increased
angiogenesis and macrophage recruitment, this suggests
that when HFD exposure is limited to adulthood these
tumor characteristics are also affected, although to a lesser
extent than when HFD is limited to peripubertal
exposure.
Microarray analysis of gene expression in tumors
Microarray analysis was performed to examine differen-
tial patterns of gene expression between early- and late-
occurring tumors that arose in the mice fed HFD, LFD,
HFD-LFD, LFD-HFD. Comparison of tumors that arose
in mice fed continuous HFD (n = 9) vs. those fed con-
tinuous LFD (n = 3) yielded no significant difference in
their patterns of gene expression (data not shown), sug-
gesting that the effects of diet on tumor characteristics
were indirect. That is, diet affected tumorigenesis by
decreasing latency, with resulting changes in gene ex-
pression for early- vs. late-onset tumors. Comparison of
animals with early tumors (n = 7) vs. late tumors (n = 18)
yielded 770 genes. A hierarchical cluster of these genes
resulted in two main sample clusters (Fig. 4). The first
cluster (upregulated in early-onset tumors) was enriched,
but not exclusively, for adenosquamous histology and,
importantly, for both continuous HFD and peripubertal
HFD (HFD-LFD) vs. continuous LFD and adult HFD
(LFD-HFD). This reinforces the conclusion that peripu-
bertal exposure to HFD is sufficient to promote tumori-
genesis similarly to continuous exposure to HFD [6].
In ontology analyses (Additional file 3: Table S3), we
identified several statistically significant (i.e., p < 0.05)
canonical pathways altered in the short latency tumors
that cluster together. Upregulated pathways included
those involved in cell cycle regulation (i.e., G1/S check-
point regulation, G2/M DNA damage checkpoint regula-
tion, cyclins and cell cycle regulation, antiproliferative
(See figure on previous page.)
Fig. 2 Tumor characteristics based on histopathology. a Mice that were on the high saturated animal fat diet (HFD) and were switched to the low-fat
diet (HFD-LFD) had an increased proportion of adenosquamous tumors compared with mice on the HFD that were switched to LFD (LFD-HFD)
(HFD-LFD 55 % vs. LFD-HFD 0 %). *p < 0.05. Conversely, LFD-HFD-fed mice had an increased proportion of nonadenosquamous tumors compared
with HFD-LFD-fed mice (LFD-HFD 100 % vs. HFD-LFD 45 %). *p < 0.05. b Adenosquamous tumors (n = 6) in HFD-LFD-fed mice had reduced latency
compared with other tumor types (n = 5). *p < 0.05. c Both adenosquamous and other mammary tumor types had increased proliferation in HFD-LFD-
fed mice compared with tumors in LFD-HFD-fed mice (n = 6). *p < 0.05. b and c Bars represent mean ± standard error of the mean (SEM). d HFD-fed
(n = 29 tumors) and LFD-fed (n = 16 tumors) mice had a similar incidence of all tumor types. e HFD-fed mice had reduced tumor latency for both
adenosquamous (n = 12) and other tumor types (n = 17) compared with total tumors in LFD-fed mice (adenosquamous, n = 5; other, n = 11). *p < 0.05.
f Adenosquamous tumors from HFD-fed mice had increased proliferation compared with all other tumors in HFD- and LFD-fed mice. *p < 0.05. b, c, e,
and f Bars represent mean ± SEM. g Incidence of estrogen receptor– and progesterone receptor–negative (ER − PR−) tumors was increased among
HFD-early (n = 11 of 12) and HFD-LFD-early (n = 6 of 6) tumors compared with LFD (n = 4 of 16), HFD-late (n = 2 of 5), LFD-HFD (n = 0 of 6), and
HFD-LFD-late (n = 2 of 5) tumors. *p < 0.05. BrdU 5-bromo-2′-deoxyuridine, DMBA 7,12-dimethylbenz[a]anthracene
Fig. 3 Overall tumor characteristics in HFD-, LFD-, HFD-LFD-, and
LFD-HFD-fed mice. a Blood vessel density (CD31 staining) was
increased in LFD-HFD-fed murine mammary tumors (#p = 0.07) and
significantly increased in HFD- and HFD-LFD-fed murine mammary
tumors compared with LFD-fed murine mammary tumors. *p < 0.05. b
Macrophage (Macs; F4/80 staining) recruitment was increased within
the stroma of tumors from mice fed a HFD-LFD vs. LFD-HFD. *p < 0.05.
Bars represent mean ± standard error of the mean; n = 4–10 tumors
per diet treatment. Arg1 arginase 1, HFD high saturated animal fat diet,
HFD-LFD mice on high saturated animal fat diet switched to low-fat
diet, LFD low-fat diet, LFD-HFD mice on low-fat diet switched to high
saturated animal fat diet
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role of TOB in T cell signaling, cell cycle control of
chromosomal replication) and organismal growth [i.e.,
mechanistic target of rapamycin (mTOR) signaling, pur-
ine nucleotides de novo biosynthesis II], genotoxic stress
[i.e., growth arrest and DNA damage 45 (GADD45) sig-
naling, eukaryotic initiation factor 2 (EIF2) signaling],
and molecular mechanisms of cancer. Downregulated
pathways included those involved in suppressing prolif-
eration and/or increasing apoptosis of breast cancer cells
[i.e., farnesoid X receptor (FXR)/retinoid X receptor
(RXR) activation, liver X receptor (LXR)/RXR activation)
and classical inflammatory processes (i.e., coagulation
system, acute phase response signaling).
Expression analysis of genes associated with HFD
promotion of tumor development
We performed qRT-PCR for expression of RNAs that
were previously reported to be either significantly upreg-
ulated or downregulated in short latency mammary tu-
mors that developed in continuous HFD mice (HFD-
early) [6]. Results were compared for fold changes of
HFD-early and HFD-late tumors vs. LFD tumors
(Table 2) and of HFD-LFD-early and HFD-LFD-late
tumors vs. LFD-HFD tumors (Table 3). HFD-early and
HFD-late tumors were distinguishably different from
each other. HFD-LFD-early tumors showed significant
upregulation of RNAs for Ntf3, Trp53, Ccnd2, Ctnnb1,
Brca1, Apaf1 and Bmp7, as well as downregulation of
Bmp10. This showed excellent concordance with our
previously published observations for these genes in
HFD-early tumors [6] (see HFD-early in Table 2). HFD-
LFD-late tumors showed a pattern of expression among
these genes more similar to that in LFD-HFD tumors,
and distinguishably different from that in the early occur-
ring HFD-LFD tumors. Compared with HFD-LFD-early
tumors, quite modest increases were observed for Ccnd2,
Ctnnb1, and Brca1 expression in the HFD-LFD-late
tumors, while Trp53 expression was modestly reduced.
No significant alterations in expression were observed for
the other genes. These results confirm that the HFD-LFD-
Fig. 4 Microarray heat map cluster analysis. The heat map and dendrogram represent a two-class significance analysis of genes differentially
expressed between early vs. late tumor onset and high saturated animal fat diet (HFD) vs. a low-fat diet (LFD). Two gene clusters were identified:
one enriched for genes upregulated among early-occurring tumors (gray bar) and one enriched for genes downregulated among early-occurring
tumors (black bar). Early-occurring tumors from HFD- and HFD-LFD-fed mice cluster together. Diet group, early vs. late tumor onset, and adenosquamous
vs. other histologies are noted. HFD-LFD mice on high saturated animal fat diet switched to low-fat diet, LFD-HFD mice on low-fat diet switched to high
saturated animal fat diet
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early tumors retain the same basal-like gene expression
pattern observed for the HFD-early tumors in our previ-
ous study [6].
Analysis of dietary effects on mammary glands before
tumor development
Because 6 weeks on HFD (i.e., HFD-LFD) was sufficient
to promote tumor development similar to continuous
HFD, we were interested in analyzing the effects of HFD
before tumor development to elucidate potential under-
lying mechanisms. We had previously noted that in-
creased numbers of mammary hyperplastic lesions,
increased angiogenesis, and increased macrophage re-
cruitment were associated with increased tumor inci-
dence and reduced latency in mice fed a continuous
HFD [6]. Thus, we analyzed these same factors in HFD-
LFD and LFD-HFD mammary glands at 4 weeks after
diet switches. These glands were taken from mice of the
same age (13 weeks of age) for comparison with con-
tinuous diet analyses (Fig. 5). The number of epithelial
hyperplastic lesions was significantly greater in HFD-
LFD mammary glands than in LFD-HFD mammary
glands (Fig. 5a). Proliferation in normal glandular struc-
tures and hyperplastic lesions was significantly increased
in HFD-LFD compared with LFD-HFD mammary glands,
similarly to continuous HFD compared with continuous
LFD mammary glands (Fig. 5b). Macrophage recruitment
to the periepithelial mammary stroma of glandular struc-
tures and hyperplastic lesions was significantly increased
for both HFD-LFD and LFD-HFD mammary glands com-
pared with continuous LFD mammary glands (Fig. 5c)
and similar to that previously reported for continuous
HFD mammary glands [6]. However, neither HFD-LFD
nor LFD-HFD increased angiogenesis in mammary glands
compared with continuous LFD, as was the case with con-
tinuous HFD mice (Fig. 5d).
HFD modulation of mammary gland gene expression
before tumor development
To gain insight into potentially specific effects of peripu-
bertal HFD vs. adult HFD exposures in tumor develop-
ment, we analyzed RNA expression by qRT-PCR of
genes that we had previously reported to be either sig-
nificantly upregulated or downregulated by continuous
Table 3 Gene expression in switched diet DMBA-induced tumors
Fold regulation (compared with LFD-HFD)
Symbol Description HFD-LFD-early HFD-LFD-late
Ntf3 Neurotrophin 3 70.0 NS
Trp53 Transformation related protein 53 1.5 −1.2
Ccnd2 Cyclin D2 12.4 3.1
Ctnnb1 Catenin (cadherin associated protein), beta 1 5.4 1.4
Brca1 Breast cancer 1 2.9 1.4
Apaf1 Apoptotic peptidase activating factor 1 1.4 NS
Bmp7 Bone morphogenetic protein 7 5.6 NS
Bmp10 Bone morphogenetic protein 10 −2.7 NS
DMBA 7,12-dimethylbenz[a]anthracene HFD high saturated animal fat diet, HFD-LFD, mice on high saturated animal fat diet switched to low-fat diet, LFD low-fat
diet, LFD-HFD mice on low-fat diet switched to high saturated animal fat diet
p < 0.05 for all genes listed, except NS = no significant change [n = 4 tumors per diet group (LFD-HFD, HFD-LFD-early, HFD-LFD-late)]
Table 2 Gene expression in continuous diet DMBA-induced tumors
Fold regulation (compared with LFD)
Symbol Description HFD-earlya HFD-late
Ntf3 Neurotrophin 3 53.4 6.3
Trp53 Transformation related protein 53 1.6 NS
Ccnd2 Cyclin D2 3.5 3.5
Ctnnb1 Catenin (cadherin associated protein), beta 1 1.8 −3.6
Brca1 Breast cancer 1 1.8 −1.5
Apaf1 Apoptotic peptidase activating factor 1 1.8 1.3
Bmp7 Bone morphogenetic protein 7 3.2 NS
Bmp10 Bone morphogenetic protein 10 −3.4 NS
DMBA 7,12-dimethylbenz[a]anthracene HFD high saturated animal fat diet, LFD low-fat diet
p < 0.05 for all genes listed, except NS = no significant change [n = 4 tumors per diet group (LFD, HFD-early, HFD-late)]
aHFD-early data from Zhao et al. [6]
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Fig. 5 Effect of various diets on mammary glands at 13 weeks of age and before tumor development. a More hyperplastic lesions (hyperplasias)
developed in HFD- and HFD-LFD-fed, 7,12-dimethylbenz[a]anthracene-treated mice. *p < 0.05. b Mice fed HFD or HFD-LFD exhibited increased
cellular proliferation in both normal epithelium and hyperplastic lesions (hyperplasia) compared with those fed LFD or LFD-HFD, respectively, as
measured by 5-bromo-2′-deoxyuridine incorporation. *p < 0.05. c Macrophage (F4/80-stained cells) recruitment was increased adjacent to normal
ducts and hyperplastic lesions (hyperplasia) (*p < 0.05) in mammary glands of HFD-, HFD-LFD-, and LFD-HFD-fed mice compared with those of
LFD-fed mice. d Blood vessel density (CD31 staining) was significantly increased adjacent to normal mammary gland structures and hyperplastic
lesions (hyperplasia) (*p < 0.05) in HFD-fed compared with LFD-, HFD-LFD-, or LFD-HFD-fed mice. Bars represent mean ± standard error of the
mean (n = 5 mice per diet group for each assay). HFD high saturated animal fat diet, HFD-LFD mice on high saturated animal fat diet switched to
low-fat diet, LFD low-fat diet, LFD-HFD mice on low-fat diet switched to high saturated animal fat diet
Table 4 RT-PCR analysis of gene expression at 13 weeks old with DMBA treatment
Fold regulation (compared with LFD)
Symbol Description HFD LFD-HFD HFD-LFD
Tgfa Transforming growth factor alpha 2.4 2.1 2.0
Ccl1 Chemokine (C-C motif) ligand 1 3.8 3.2 NS
Ccl17 Chemokine (C-C motif) ligand 17 2.8 4.0 NS
Ccl20 Chemokine (C-C motif) ligand 20 11.0 5.0 NS
Ccl22 Chemokine (C-C motif) ligand 22 4.0 6.1 NS
Tgfb1 Transforming growth factor, β 1 1.6 2.2 NS
DMBA 7,12-dimethylbenz[a]anthracene HFD high saturated animal fat diet, HFD-LFD, mice on high saturated animal fat diet switched to low-fat diet, LFD low-fat
diet, LFD-HFD mice on low-fat diet switched to high saturated animal fat diet, RT-PCR reverse transcription polymerase chain reaction
p < 0.05 for all genes listed, except NS = no significant change (n = 4 mice per diet treatment)
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HFD in mammary glands before tumor development [6].
The results were compared for fold changes between
HFD, HFD-LFD, and LFD-HFD vs. LFD. The RNA levels
of Tgfa, Tgfb1, and the chemokines Ccl1, Ccl17, Ccl20,
and Ccl22 were analyzed (Table 4). HFD, HFD-LFD, and
LFD-HFD mammary glands all exhibited significant, ap-
proximately twofold increases in Tgfa RNA compared
with LFD mammary glands. No significant changes were
observed in the RNA levels of Tgfb1 and the other
assayed chemokines in HFD-LFD mammary glands;
however, these RNAs were upregulated in LFD-HFD
mammary glands to a similar extent as in HFD mammary
glands. Comparisons made for HFD-LFD vs. LFD-HFD
were consistent with these results (data not shown). This
suggests an association with adult HFD and not with the
peripubertal HFD promotional window. Furthermore,
these results suggest that both peripubertal-only and
adult-only HFD exposure increase Tgfa RNA levels, simi-
larly to continuous HFD exposure.
Immunofluorescence determination of β-catenin expression
associated with HFD promotion of tumor development
Previously, we identified basal-like breast cancer gene
expression characteristics in our gene ontology analysis
of HFD early tumors [6]. The key genes identified were
elements of the β-catenin signaling pathway, including
β-catenin itself. Analysis of β-catenin expression by im-
munofluorescence in pretumor mammary glands showed
increased expression in HFD-LFD mice (approximately
1.5-fold, p < 0.05) and a trend toward increased expression
in continuous HFD mice (approximately twofold; p = 0.08)
(Fig. 6).
Analysis of β-catenin immunofluorescence in tumors
(Fig. 7) showed similar levels in adenosquamous tumors
arising in continuous LFD or HFD mice with regard to
overall intensity and nuclear staining scores (Fig. 7a, b). For
all other tumor types (i.e., glandular, cribriform, papillary,
ductal), β-catenin levels were significantly higher in the
continuous HFD group (p < 0.05) compared with the con-
tinuous LFD group and exhibited an increased nuclear
score that approached statistical significance (p = 0.09). In
HFD-LFD and LFD-HFD tumors, β-catenin immunofluor-
escence levels were similar and comparable to continuous
HFD tumors, regardless of histopathological type (Fig. 7c).
There were no differences in their nuclear staining scores
Fig. 6 β-catenin regulation by diet treatment in mammary glands at
13 weeks of age. Before tumor development, β-catenin levels were
measured based on immunofluorescence. β-catenin levels were
increased by HFD (p = 0.08) and HFD-LFD. *p < 0.05. Bars represent
mean ± standard error of the mean (n = 5 mice per diet treatment).
HFD high saturated animal fat diet, HFD-LFD mice on high saturated
animal fat diet switched to low-fat diet, LFD low-fat diet, LFD-HFD
mice on low-fat diet switched to high saturated animal fat diet
Fig. 7 β-catenin regulation by diet treatment in tumors. β-catenin levels
were measured based on immunofluorescence intensity or nuclear
localization in adenosquamous (ADSQ) and nonadenosquamous (Other)
tumors. a β-catenin levels were increased in nonadenosquamous
tumors from HFD-fed mice (HFD Other) compared with those from
LFD-mice (LFD Other). *p< 0.05. b These same tumors from HFD-fed
mice (HFD Other) showed a trend toward increased nuclear β-catenin
compared with nonadenosquamous tumors from LFD-fed mice (LFD
Other) (p = 0.09). c Tumors from HFD-LFD- and LFD-HFD-fed mice had
similar β-catenin levels. Bars represent mean ± standard error of the
mean (n = 4–8 tumors per diet treatment). HFD high saturated animal
fat diet, HFD-LFD mice on high saturated animal fat diet switched to
low-fat diet, LFD low-fat diet, LFD-HFD mice on low-fat diet switched to
high saturated animal fat diet
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(data not shown). Elevated β-catenin appeared to be posi-
tively associated with adenosquamous tumors, regardless of
diet, and HFD exposure at any life stage, whether peripub-
erty or adulthood, resulted in elevated β-catenin across the
various nonadenosquamous tumor histopathologies.
Dietary effects on metabolic parameters, and systemic
factors
As shown in Additional file 4: Figure S1, increased body
weight was observed in the LFD-HFD mice, most not-
ably starting at 23 weeks of age. This weight gain aver-
aged 10 % over that in other dietary regimens. This is in
contrast to the previous finding that continuous HFD
initiated in peripuberty did not increase body weight [6].
However, it is noteworthy that, despite the increase in
body weight, this did not promote tumor development
as measured by increased incidence, decreased latency,
or increased tumor cell proliferation in the LFD-HFD
tumors (see Figs. 1 and 2). Additionally, despite the in-
crease in body weight observed in the LFD-HFD mice,
there were no significant differences in blood glucose or
insulin levels between tumor-bearing HFD-LFD and
LFD-HFD mice. Analysis of blood glucose and insulin
levels showed that there were no significant differences
between diet regimens at 4 weeks after diet switches
(Additional file 5: Figure S2).
Interactions between peripubertal HFD and peripubertal
DMBA exposure
We considered the possibility that some of the observed
HFD effects were the result of interactions between diet
and peripubertal carcinogen exposure. To examine this
possibility, we analyzed the peripubertal effects of HFD
in the absence of carcinogen treatment. We previously
reported alterations in proliferation, immune function,
and gene expression at 3 and 4 weeks of exposure to
HFD in the absence of DMBA treatment [6]. At 10 weeks
on diets without DMBA treatment, there were no
significant differences in mammary epithelial cell prolif-
eration for continuous HFD vs. continuous LFD or
HFD-LFD vs. LFD-HFD (Fig. 8a). No significant effects
on blood vessel density were observed comparing HFD-
LFD mice with LFD-HFD mice that were not treated
with DMBA (Fig. 8b). As noted above (Fig. 5d), DMBA-
treated mice exposed to HFD over their life course had
increased vascularity compared with mice with continu-
ous LFD exposure. The overall blood vessel density was
higher in the mammary glands of mice that did not
receive DMBA treatment than in those that were treated
with DMBA (data not shown). In the absence of DMBA
treatment, macrophage recruitment was significantly in-
creased in HFD-LFD mammary glands and similar to
that in animals fed continuous HFD, whereas LFD-HFD
mammary glands did not show increased recruitment
(Fig. 8c). Macrophage recruitment was generally lower in
the absence of DMBA treatment under all diet conditions
(data not shown). As noted above (Fig. 5c), DMBA-treated
mice exposed to HFD at peripuberty, adulthood, or
throughout their life course exhibited increased macro-
phage recruitment. The overwhelming majority of macro-
phages under all conditions were Arg1-positive, indicating
a preponderance of M2 alternatively activated macro-
phages (data not shown). Collectively, these data suggest
that pubertal exposure is critical for macrophage
Fig. 8 Effects of diet with or without 7,12-dimethylbenz[a]anthracene
(DMBA) treatment in the mammary gland at 13 weeks of age. a
Proliferation in mammary glands from mice fed HFD, LFD, HFD-LFD, or
LFD-HFD was measured by 5-bromo-2′-deoxyuridine incorporation.
Only diet treatments with DMBA increased proliferation (*p < 0.05). b
Only HFD with DMBA increased blood vessel density (CD31 staining)
compared with all other diet treatments (*p < 0.05). c HFD with or
without DMBA and HFD-LFD without DMBA increased macrophage
recruitment (F4/80 staining) compared with LFD and LFD-HFD without
DMBA. *p < 0.05. Bars represent mean ± standard error of the mean
(n = 5 mice per diet and DMBA treatment). HFD high saturated animal
fat diet, HFD-LFD mice on high saturated animal fat diet switched to
low-fat diet, LFD low-fat diet, LFD-HFD mice on low-fat diet switched to
high saturated animal fat diet
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recruitment. Furthermore, these results show that in-
creased macrophage recruitment was a result of HFD ex-
posure itself and not a result of diet interaction with
carcinogens.
When we analyzed the effects of diet on gene expres-
sion in the pretumor mammary glands (13 weeks of age)
of mice that had been treated with DMBA or untreated,
we found that none of the genes upregulated by HFD in
DMBA-treated mice (Table 5) showed significant
changes in gene expression in untreated mice. This sug-
gests that the gene expression changes that we observed
in pretumor animals were the result of interaction be-
tween HFD and prior DMBA treatment.
We also examined the effect of diet on mammary gland
morphology of DMBA-treated and untreated mice at
10 weeks on diet (13 weeks of age) (Fig. 9). There was a
striking difference in overall morphology. In DMBA-
treated mice, the presence of terminal end buds along
with reduced branching of the ductal tree was seen in the
adult 13-week-old mammary glands. This was true for
both LFD and HFD mice. Hyperplasia was also noted in
HFD mammary glands. In contrast, both LFD and HFD
Table 5 Effect of diet alone vs diet + DMBA on gene expression at 13 weeks old
Fold regulation (compared with LFD)
Symbol Description HFD + DMBA HFD alone
Tgfa Transforming growth factor alpha 2.4 NS
Ccl1 Chemokine (C-C motif) ligand 1 3.8 NS
Ccl17 Chemokine (C-C motif) ligand 17 2.8 NS
Ccl20 Chemokine (C-C motif) ligand 20 11 NS
Ccl22 Chemokine (C-C motif) ligand 22 4 NS
Tgfb1 Transforming growth factor, β1 1.6 NS
DMBA 7,12-dimethylbenz[a]anthracene, HFD high saturated animal fat diet, LFD low-fat diet
p < 0.05 for all genes listed, except NS = no significant change (n = 4 mice per diet treatment)
Fig. 9 Effects of high saturated animal fat diet (HFD) with and without 7,12-dimethylbenz[a]anthracene (DMBA) on mammary gland morphology.
Mammary gland morphology was assessed from whole mounts of mice fed HFD or a low-fat diet (LFD) with or without DMBA from 3 to 13 weeks
of age. Mammary glands from either DMBA-treated HFD- or LFD-fed mice retained a pubertal ductal organization with numerous terminal end
buds present (indicated by arrows). In the absence of DMBA, HFD- and LFD-fed mice exhibited a mature morphology indicated by extensive
ductal branching and presence of ductal side branches (indicated by arrowheads). Representative photomicrographs of five mice per diet and
DMBA treatment are shown. Scale bar = 1 mm
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mice without DMBA treatment displayed well-developed
mammary glands with extensive ductal branching and side
branch development indicative of mammary gland matur-
ation (Fig. 9). There was no specific effect of diet itself on
mammary gland morphology, and thus the differences ap-
peared to be due to DMBA treatment.
Discussion
In this study, we showed that HFD restricted to peripub-
erty reduced the latency of DMBA-induced mammary
tumors and led to tumors with characteristics very simi-
lar to those occurring in mice fed a continuous HFD.
Notably, the tumors occurring after HFD limited to peri-
puberty shared characteristics with basal-like human
breast cancers. The incidence of basal-like, triple-
negative, adenosquamous tumors was significantly in-
creased among the short-latency tumors. On the basis of
genomic and immunohistochemical analysis, adenosqua-
mous human breast carcinomas are a rare variant of
basal-like carcinomas [16]. It is notable that the inci-
dence of adenosquamous tumors in young, ovary-intact
mice temporally parallels the increased occurrence of
human basal-like breast cancer in younger women [3].
The short-latency tumors showed elevated rates of prolif-
eration, increased numbers of macrophages, and en-
hanced vascularization. Increased proliferation, increased
hyperplasia, and increased numbers of macrophages were
observed in mammary glands before the occurrence of tu-
mors, implicating these characteristics as plausible effec-
tors of tumor promotion as a result of peripubertal HFD
exposure.
Pubertal window of susceptibility
HFD restricted to peripuberty (HFD-LFD) reiterates the
effects of a continuous HFD (HFD) and points to a pu-
bertal window of susceptibility for HFD promotion of
tumorigenesis. The short-latency tumors observed in the
present study with HFD-LFD were similar to tumors
that developed with HFD [6] with regard to histopath-
ology. Both groups of tumors (HFD and HFD-LFD) were
predominantly epithelial in origin, with a significant
adenosquamous component, and were triple-negative
(ER−PR−Her2−), similar to a subset of basal-like human
breast cancers. It is noteworthy that switching to LFD in
adulthood does not reverse peripubertal HFD-enhanced
tumorigenesis. Furthermore, no promotional effect was
observed in LFD-HFD mice, despite the long duration of
HFD exposure, approaching that of continuous HFD.
The data collectively support the idea of a pubertal win-
dow of susceptibility to HFD for its most profound
effects on tumorigenesis and that those effects are most
profound on basal-like, adenosquamous tumors.
HFD and tumor latency
Apart from adenosquamous tumors, all other histotypes
also had shorter latency in HFD mice than in LFD mice.
Glandular, cribriform, and papillary tumors did not show
reduced latency in HFD-LFD mice and had a similar
incidence in mice on continuous HFD and LFD. Because
both continuous HFD and LFD-HFD mice received
quite lengthy HFD exposure, the length of treatment is
unlikely to be the explanation for this difference in la-
tency for nonadenosquamous tumors in HFD mice. Ra-
ther, the reduced latency of nonadenosquamous tumors
in HFD mice is likely dependent upon a puberty-specific
effect of HFD that additionally requires adult HFD ex-
posure to promote these tumors. We speculate that the
increased proliferation observed in normal mammary
epithelium of both continuous HFD and HFD-LFD
mice, coupled with elevated angiogenesis that is ob-
served only in continuous HFD, is responsible. In our
earlier studies [6], we found that Vegfa expression
was increased in the mammary glands of mice fed
continuous HFD, and this may play a role in elevated
angiogenesis.
Interestingly, LFD-HFD tumors showed trends toward
increased angiogenesis and macrophage recruitment that
did not reach statistical significance, which suggests that
HFD exposure limited to adulthood also affected these
tumor characteristics, although to a lesser extent than
peripubertal HFD exposure and not translating to in-
creased tumor incidence or reduced tumor latency.
Gene expression characteristics of tumors
qRT-PCR showed similar patterns of gene expression in
both early HFD-LFD and HFD tumors, in accord with
their similar phenotypic characteristics. Regulation of
the same genes was observed across adenosquamous
and epithelial histotypes. Microarray analysis also
strongly supported the similarity of early HFD and
HFD-LFD tumors, showing that all of these tumors clus-
ter together, in contrast to tumors from mice on other
dietary regimens and/or tumors that occur with longer
latency. Notably, only mice exposed to HFD during pu-
berty developed early tumors. Interestingly, although
peripubertal HFD particularly promoted the occurrence
of adenosquamous tumors, the gene clusters associated
with early tumors in the microarray analysis were drawn
from epithelial as well as adenosquamous tumors. In-
deed, epithelial carcinomas also showed reduced latency
in mice fed continuous HFD. Only one late-occurring
tumor clustered with an otherwise uniform collection of
early tumors. This tumor had an adenosquamous pheno-
type, whereas two other adenosquamous tumors clustered
with late tumors. It is possible that the adenosquamous
phenotype contributes to the observed early signature, but
the uniform clustering of early tumors vs. the more
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diverse clustering of adenosquamous tumors suggests a
temporal rather than a histological signature for this clus-
ter. Collectively, the data from qRT-PCR of specific RNAs
and from microarrays are most consistent with a gene
expression signature for early-occurring tumors, regard-
less of histology. It remains to be determined whether the
observed pattern of gene expression is reflective of peripu-
bertal HFD or early occurrence of the tumors.
Examination of the existing literature reveals that, in
addition to DMBA-induced mammary tumors, other
mouse models that show a similarly high presentation of
squamous-like mammary tumors are the Brg1+/− [17]
and Pik3ca-H1047R [18] models, the squamous tumors
of which were shown by gene set analysis to be similar
to claudin-low human breast tumors [19]. It remains to
be determined whether the adenosquamous tumors
identified in our study are similar to claudin-low human
breast tumors in their pattern of gene expression.
HFD and HFD-LFD tumors showed significant simi-
larities with regard to increased proliferation, increased
angiogenesis, and increased macrophage recruitment,
which indicates that peripubertal HFD treatment had a
lasting effect on tumor phenotype. Consistent with en-
hanced proliferation, Ingenuity Pathway Analysis of the
upregulated microarray gene cluster associated with the
early occurring HFD and HFD-LFD tumors highlighted
canonical pathways associated with proliferative pro-
cesses (i.e., G1/S checkpoint regulation, G2/M DNA
damage checkpoint regulation, cyclins and cell cycle
regulation, antiproliferative role of TOB in T cell signaling,
mTOR signaling, purine nucleotides de novo biosynthesis
II, cell cycle control of chromosomal replication, and mo-
lecular mechanisms of cancer). Also consistent with en-
hanced proliferation, downregulated pathways associated
with suppressing proliferation and/or increasing apoptosis
of breast cancer cells (i.e., FXR/RXR activation and LXR/
RXR activation) [20–22] were also identified. Other down-
regulated pathways are consistent with anti-inflammatory
processes (i.e., coagulation system and acute-phase re-
sponse signaling). The early HFD tumors showed higher
levels of Arg1-positive macrophages [6], indicative of M2
or alternative anti-inflammatory activation. Although early
HFD-LFD tumors did not show elevated levels of M2
macrophages, these pathways were not as robustly down-
regulated in those tumors. Additionally, pathways associ-
ated with genotoxic stress (i.e., GADD45 signaling, DNA
damage-induced 14-3-3σ signaling, and EIF2 signaling)
were identified among upregulated genes. This may be as-
sociated with DNA damage resulting from exposure to
the mutagenic carcinogen DMBA.
qRT-PCR showed upregulation of Ntf3, Trp53, Ccnd2,
Ctnnb1, Brca1, Apaf1, and Bmp7 RNAs and downregu-
lation of Bmp10 RNA in both early HFD and early HFD-
LFD tumors. We previously found that Trp53, Bmp7,
Ctnnb1, and Bmp10 identified Ingenuity canonical path-
ways for basal cell carcinoma signaling and role of
NANOG in mammalian embryonic stem cell pluripo-
tency [6]. This suggests that the similarity between HFD
early tumors and basal-like breast cancer [23] is reiter-
ated in the HFD-LFD early tumors. In our prior studies
[6], Trp53, Ctnnb1, Ccnd2, Brca1, and Apaf1 also identi-
fied Ingenuity canonical pathways for p53 signaling and
GADD45 signaling. This confirms our findings in In-
genuity Pathway Analysis of the microarray clusters.
Trp53, Ctnnb1, Bmp7, Bmp10, Ccnd2, Apaf1, and Brca1
additionally identified the Ingenuity canonical pathway
for molecular mechanisms of cancer, again confirming
our findings from Ingenuity Pathway Analysis of the
microarray clusters.
Ntf3 and its receptor Ntrk3, though they do not iden-
tify a canonical pathway, are overexpressed in a signifi-
cant proportion of human breast cancers, particularly in
basal-like breast cancers (11 % amplified + upregulated
in basal-like PAM50 breast cancers vs. 5 % in all breast
cancers, 6 % in luminal A/B, and 0 % in Her2+) [24, 25].
Neurotrophins and the p75 neurotrophin receptor are
expressed in human breast cancers and are implicated
in promoting angiogenesis, tumor growth, invasion,
resistance to apoptosis, and resistance to anoikis in
triple-negative breast cancer [26–28]. Interestingly,
neurotrophin expression is increased in the brains of
mice fed 60 % HFD, suggesting its upregulation in
early-occurring continuous HFD and HFD-LFD tumors
may also be diet-induced [29].
The increased expression of Ccnd2 (cyclin D2) is dis-
cordant with enhanced tumorigenesis of early continu-
ous HFD and HFD-LFD tumors, as loss of cyclin D2
expression is frequent in breast cancers [30] and cyclin
D2 has been considered to be a tumor suppressor. How-
ever, transgenic overexpression of cyclin D2 does block
lobuloalveolar development [31], and perhaps Ccnd2
overexpression in our system could be viewed as suppress-
ing differentiation. It is noteworthy that Ccnd2 expression
may be specifically elevated in poorly differentiated breast
cancer cells that exhibit features of epithelial-mesenchymal
transition and a higher potential for metastasis [32]. Exam-
ination of The Cancer Genome Atlas database revealed that
Ccnd2 expression was altered (mainly amplified or upregu-
lated) in 16 % of basal-like PAM50 breast cancers vs.
altered (mainly downregulated) in 4 % of luminal A/B and
0 % in Her2+ breast cancers [24, 25].
In regard to increased Ctnnb1 (β-catenin) expression,
the Wnt/β-catenin pathway is involved in normal mam-
mary gland proliferation and development and is associ-
ated with poor prognosis in breast cancer [33]. Elevated
Ctnnb1 expression may activate this pathway. We found
that β-catenin protein and activation levels were elevated
in all adenosquamous tumors regardless of diet, and
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thus this is unlikely to be a factor in their shortened
latency on continuous HFD and HFD-LFD. β-catenin
levels were also elevated in the nonadenosquamous con-
tinuous HFD tumors, as well as in nonadenosquamous
switched-diet tumors. Thus, elevated β-catenin is associ-
ated with adenosquamous tumors regardless of diet, and
HFD exposure in any life period results in elevated β-
catenin across the various other nonadenosquamous
tumor histopathologies. Because both HFD-LFD and
HFD elevate β-catenin but HFD-LFD does not shorten
the latency of nonadenosquamous tumors, it is unlikely
that β-catenin is key to driving shortened latency in the
nonadenosquamous tumors from HFD mice. As men-
tioned above, increased angiogenesis is a more likely
mechanism, as it requires continuous HFD exposure.
Characteristics of the mammary gland before the
occurrence of tumors
We previously reported that, before tumor development,
continuous HFD mice exhibited increased proliferation
in normal mammary gland structures and hyperplastic
lesions, as well as increased incidence of abnormal
hyperplasia, associated with increased tumorigenesis [6].
The pretumor mammary glands of HFD-LFD mice were
similar in all of these characteristics, and these factors
were all likely important contributing factors in promot-
ing tumor development after peripubertal HFD expos-
ure. In contrast, macrophage recruitment was increased
in all treatment groups that received HFD, regardless of
timing, whereas increased angiogenesis required con-
tinuous HFD exposure. These latter results suggest that,
if macrophage recruitment plays a role in HFD tumor
promotion, it is likely through interaction with an effect
specific to peripubertal exposure or with a property of
the gland at this stage of development. With regard to
angiogenesis, only continuous exposure to HFD was suf-
ficient for this, and thus it was not a contributing factor
to the peripubertal HFD promotional effects.
Gene expression analysis in pretumor mammary
glands showed that all growth factors and chemokines
observed to be elevated before tumor development in
continuous HFD mice at 13 weeks of age (i.e., Tgfa, Ccl1,
Ccl17, Ccl20, Ccl22, and Tgfb1) were elevated in LFD-
HFD mammary glands at this time. Because LFD-HFD
mammary glands do not develop early tumors, this indi-
cates that these factors are unlikely to be factors specific
to peripubertal exposure or to be responsible for the en-
hanced proliferation observed in normal HFD-LFD
mammary glands. Only Tgfa was elevated in HFD-LFD
mammary glands at a time after the switch to LFD. If in-
creased Tgfa levels were sustained throughout the
tumorigenesis period (up to 45 weeks of age) in the
HFD-LFD group and did not require continued HFD
exposure, this could explain, at least in part, the
promotional effect of limited peripubertal exposure to
HFD. Ctnnb1 (β-catenin) expression was also increased
in pretumor mammary glands of HFD-LFD mice and
showed a trend toward increased expression in continu-
ous HFD mice, indicating another early effect of peripu-
bertal exposure to HFD. It is noteworthy that TGFα can
activate β-catenin [34]. This further suggests a plausible
role for TGFα in HFD-enhanced proliferation. However,
TGFα itself is certainly not sufficient to promote prolif-
eration, as elevated Tgfa expression and proliferation are
dissociated in mice exposed to HFD only in adulthood
(i.e., LFD-HFD). It may be that peripubertal HFD expos-
ure induces another growth factor not assayed here, per-
haps through the action of TGFα itself; that peripubertal
HFD exposure induces long-lasting changes in the regu-
lation of proliferation (e.g., epigenetic effects); or that
peripubertal TGFα interacts with a specific population
of cells not present in the adult gland (e.g., stem cells).
The length of exposure to elevated levels of TGFα is a
less likely explanation, as brief peripubertal exposure
and lengthy continuous exposure to HFD elicit similar
increases in Tgfa expression. The pubertal window of ex-
posure seems critical regardless of whether elevated Tgfa
expression is essential for enhanced proliferation. It is
noteworthy that there was no overlap between the genes
and pathways identified in pretumor mammary glands
by expression analyses at 3 or 4 weeks on HFD and
those identified at 10 weeks on HFD, as well as between
those identified at any pretumor time point and in early
HFD tumors [6].
Interaction of DMBA and HFD
We previously reported that in the absence of DMBA, at
3 weeks on HFD, there was a significant transient in-
crease in eosinophil recruitment to the periepithelial
stroma, as well as transient increases in Ccl3, Ccl24, and
Il4 gene expression; a twofold increase in mammary epi-
thelial cell proliferation; and robust upregulation of
Tnfs11 (receptor activator of nuclear factor κB ligand)
gene expression at 4 weeks on HFD [6]. However, in the
present study, in the absence of DMBA at 10 weeks on
their diets (13 weeks of age), only increased macrophage
recruitment was observed among continuous HFD and
HFD-LFD mice. Importantly, this highlights the long-
lasting effect of peripubertal HFD to cause higher levels
of macrophages that are maintained after a switch to
LFD. None of the genes identified as HFD-regulated in
DMBA-treated mice were regulated by HFD in the
absence of DMBA. Among those genes that were regu-
lated by only HFD with DMBA treatment were Tgfb1,
Ccl1, Ccl17, and Ccl22, whose products are all associated
with the recruitment and function of immunosuppres-
sive Treg cells [35–37]. Thus, the interaction of DMBA
with HFD may influence tumorigenesis by immune
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modulation in addition to its activity as a mutagen. We
also noted that DMBA, independent of diet, had a
profound effect on mammary gland development.
DMBA-treated mammary glands retained a pubertal
morphology, evidenced by the presence of numerous
terminal end buds and limited ductal growth. Because
the pubertal gland is undergoing rapid proliferation, it is
likely that the retention of a pubertal developmental
state resulting from DMBA treatment contributed to the
increased proliferative effects of HFD at 13 weeks of age,
as previously reported [6].
An additional consideration regarding the interaction
of HFD and DMBA is the possibility that HFD could in-
crease the metabolism and activation of DMBA, thereby
increasing the “effective dose” of DMBA. This could in
part contribute to the increased tumorigenesis observed
with HFD. It is also of interest to note that increasing
doses of DMBA can also increase the proportion of ade-
nosquamous mammary tumors [38]. However, it is note-
worthy that the increased incidence of early tumors and
adenosquamous tumors occurred mainly as a result of
peripubertal exposure to HFD, indicating an important
life-stage period of increased susceptibility to an HFD’s
effects.
Another consideration regarding HFD effects in the
present study are its potential contribution to tumori-
genesis through increased caloric density. Lard is the
major animal fat in our HFD, and it contributes to cal-
oric density. Researchers in other studies have compared
45 % and 60 % lard HFD, which differ in caloric density,
on tumorigenesis in C3(1)-TAg mice [39], and they found
the same increases in tumorigenesis for both 45 % and
60 % lard HFD compared with 10 % LFD. This suggests
that increased caloric density per se was not the only
contributor to increased mammary tumorigenesis. How-
ever, regardless of caloric density, excess lard is appar-
ently a risk factor for the mice; it may be the fat, or it
may be the extra calories.
It is noteworthy that mice in the present study which
were started on HFD in peripuberty did not exhibit a sig-
nificant increase in body weight. Thus, HFD had a promo-
tional effect on tumorigenesis in normal-weight mice.
Interestingly, mice started on HFD in adulthood did gain
significant body weight. However, despite the increase in
body weight, this did not promote tumor development as
measured by increased incidence, decreased latency, or in-
creased tumor cell proliferation in the LFD-HFD tumors.
Also to be considered are the metabolic consequences of
HFD with regard to the development of prediabetic or
diabetic conditions. In this regard, despite the increase in
body weight observed in the LFD-HFD mice, there were
no significant differences in blood glucose or insulin levels
between diet regimens at 4 weeks after diet switches or in
tumor-bearing HFD-LFD and LFD-HFD mice.
Studies on the effect of HFD on tumor development
without obesity have been investigated in other mouse
mammary cancer models. Results vary by age at diet initi-
ation and by tumor model. In two studies of the effects of
HFD initiated at 4 weeks of age in mice overexpressing
HER2/Neu in the mammary gland [40, 41], HFD pro-
moted tumor development by increasing tumor incidence
without increasing tumor cell proliferation, and there was
no insulin resistance or hyperinsulinemia. In contrast,
HER2/Neu-transgenic mice fed HFD starting in adulthood
showed no difference in tumor latency, incidence, or me-
tastasis [42]. In the BALB/c 4 T1 tumor transplant model,
mice were started on HFD at 4 weeks of age and tumor
cells were transplanted after 16 weeks on diet [43].
Tumor weight and number of metastases were signifi-
cantly increased by HFD. In contrast, there was no
promotional effect when HFD was initiated in 10-
week-old adult mice. The promotional effect observed
when diet was started at 4 weeks of age is similar to
our present results, showing an association of HFD
with increased macrophage infiltration, angiogenesis,
and cellular proliferation, as well as increased levels
of a number of inflammatory factors.
Conclusions
These studies importantly reveal a pubertal window of
susceptibility to HFD promotion of DMBA-induced
mammary carcinogenesis. Although the full range of
etiologic factors that contribute to human breast cancer
are yet to be determined, early life exposure to environ-
mental carcinogens is a plausible contributing factor.
Thus, the carcinogen-induced mammary cancer model
allowed us to investigate the interaction of a carcino-
genic mutagen and a lifestyle factor (dietary fat) on
subsequent promotion of mammary tumorigenesis.
Increased proliferation and increased tumor-associated
macrophages are characteristics that are maintained
in the short-latency tumors that arise after peripuber-
tal restricted HFD, and thus they are plausible con-
tributors to the promotion of tumor development
observed with peripubertal HFD exposure. Interest-
ingly, the only peripubertal HFD characteristic that
we observed in the absence of DMBA was enhanced
macrophage recruitment to the normal periepithelial
compartment. This suggests that HFD-mediated macro-
phage recruitment induced during peripubertal exposure
has the potential to influence future mammary tumor
development across tumor etiologies beyond DMBA-
induced carcinogenesis.
It is noteworthy that recent prospective human epide-
miologic studies show compelling evidence for high total
and saturated fat intake as a risk factor for ER + PR+ as
well as HER2− breast cancer [44] and, strikingly, a
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strong association between the intake of red meat–de-
rived animal fat and breast cancer risk in normal-weight,
premenopausal women but not in overweight or obese
women [5]. The latter findings are particularly in accord
with our present study, where we found that an animal-
derived HFD promoted tumor development in an
obesity-resistant mouse model of breast cancer. The
increased and early occurrence of adenosquamous
carcinomas, a subtype of mammary cancer that resem-
bles a subset of human basal-like breast cancer that also
predominantly occurs at an earlier age than other breast
cancers [3], suggests further parallels between these
human and animal studies of diet-associated carcinogen-
esis. Future studies designed to reveal the mechanisms
underlying these parallels are needed to identify po-
tential interventions for the promotional effects of
pubertal dietary exposure to animal-derived saturated
fat. These studies have the potential to reveal inter-
mediate biomarkers that may increase the ability to
assess breast cancer risk and develop intervention
strategies to reduce risk.
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